In what appears to be the worst news yet conerning any of the leading COVID-19 vaccine candidates, a patient enrolled in the trial for AstraZeneca’s COVID-19 vaccine candidate (which it’s working on with Oxford) has died.
Brazilian health authority Anvisa announced Wednesday that one of the volunteers who was participating in the study had died. The news sent the company’s ADRs to their lowest level since April, per Reuters.
AstraZeneca’s massive globe-spanning trial was put on mandatory hiatus back in September after two participants were sickened in the company’s trial in the UK, prompting authorities to close it down briefly.
However, the FDA refused to restart the trial in the US, citing vague safety-related criteria. We now await more information from AZ.
No problem if they’d use a good placebo. Sodium cyanide for instance.